Outlook Therapeutics Inc (OTLK)

[H2R]

Type A meeting within a week??

Outlook Therapeutics® Requests Type A Meeting With FDA
September 29, 2023
PDF Version
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) dated August 29, 2023 regarding the Biologics License Application (BLA) for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

Now put that together with the Cantor Fitzergarld

16'34'' OTLK will provide a briefing document to the FDA to address and at the same time will request an FDA meeting.
The FDA has 30 days to meet once the request is issued.

Putting those two together... this week for a Type A?

Best of luck with your investments.